Celcuity, Inc. (NASDAQ:CELC - Free Report) - Stock analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Celcuity in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($5.23) per share for the year, down from their previous estimate of ($4.84). HC Wainwright has a "Buy" rating and a $150.00 price objective on the stock. The consensus estimate for Celcuity's current full-year earnings is ($5.01) per share. HC Wainwright also issued estimates for Celcuity's Q4 2026 earnings at ($1.50) EPS, Q1 2027 earnings at ($1.30) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.73) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($1.38) EPS, FY2029 earnings at $1.32 EPS and FY2030 earnings at $4.00 EPS.
Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research report on Tuesday, September 1st. Guggenheim assumed coverage on shares of Celcuity in a research report on Friday, November 6th. They set a "buy" rating and a $169.00 target price on the stock. Citigroup reissued a "market outperform" rating on shares of Celcuity in a research note on Monday, November 9th. JPMorgan Chase & Co. initiated coverage on shares of Celcuity in a research note on Thursday, September 17th. They set an "overweight" rating and a $157.00 price target on the stock. Finally, Stifel Nicolaus dropped their price objective on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $151.79.
Check Out Our Latest Research Report on Celcuity
Celcuity Stock Down 4.2%
Celcuity stock opened at $58.01 on Wednesday. The stock has a 50-day simple moving average of $71.07 and a 200 day simple moving average of $97.69. The company has a quick ratio of 14.59, a current ratio of 14.62 and a debt-to-equity ratio of 6.04. Celcuity has a 12-month low of $53.54 and a 12-month high of $151.02.
Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, topping analysts' consensus estimates of ($1.51) by $0.30.
Institutional Trading of Celcuity
Several institutional investors and hedge funds have recently made changes to their positions in the business. Soleus Capital Management L.P. purchased a new position in Celcuity during the 3rd quarter worth $133,813,000. Assenagon Asset Management S.A. raised its holdings in shares of Celcuity by 685.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company's stock valued at $117,579,000 after purchasing an additional 1,290,466 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Celcuity in the second quarter valued at about $153,928,000. Wellington Management Group LLP lifted its position in shares of Celcuity by 111.4% during the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company's stock valued at $94,848,000 after purchasing an additional 477,643 shares in the last quarter. Finally, Apis Capital Advisors LLC lifted its position in shares of Celcuity by 5.4% during the third quarter. Apis Capital Advisors LLC now owns 567,200 shares of the company's stock valued at $45,104,000 after purchasing an additional 29,200 shares in the last quarter. Institutional investors own 63.33% of the company's stock.
Top Celcuity Stories
These are some of the CELC stories that stood out recently:
- Positive Sentiment: HC Wainwright kept its Buy rating and $150 target, signaling continued confidence despite the lower earnings forecasts.
- Neutral Sentiment: The firm raised its Q3 2027 EPS estimate slightly, to a loss of $0.73 per share from a projected loss of $0.80.
- Negative Sentiment: Most revisions were downward: estimates worsened for Q4 2026 and Q1–Q2 2027, as well as full-year 2026–2028. HC Wainwright also reduced its projected profits for 2029 and 2030, suggesting a slower path to profitability than previously expected. These broad cuts could pressure CELC shares.
About Celcuity
(
Get Free Report)
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.